Severity
Low
FDA Drug recall · Reported August 14, 2019
CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.
American Health Packaging recalled Lovastatin Tablets USP, 40 mg, packaged in a) 100-count bottles (NDC 68001-316-00) and b)… - a low-severity action.
Lovastatin Tablets USP, 40 mg, packaged in a) 100-count bottles (NDC 68001-316-00) and b)… was recalled by American Health Packaging in August 14, 2019. Reason: CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for indiv…. Check the official notice for the remedy. Verify recall #D-1584-2019 with the FDA Drug before acting.
The recall
American Health Packaging issued this low-severity FDA Drug recall-CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for indiv….
Sourced from official FDA Drug enforcement records. Verify recall #D-1584-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1584-2019) was formally reported on August 14, 2019, with the manufacturer initiating the action on February 19, 2019. It is classified under Low severity (Class III), with a current status of Terminated. American Health Packaging is listed as the recalling firm, operating out of Columbus, OH. Federal records list the affected scope as 14,360 bottles.
The documented reason for this recall is: CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results. Distribution data in the federal record shows the product reached: Nationwide within the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
14,360 bottles
Related Recalls
6
5 from same agency
Lovastatin Tablets USP, 40 mg, packaged in a) 100-count bottles (NDC 68001-316-00) and b)1000-count bottles (NDC 68001-316-08), Rx Only, Manufactured by: Lupin Limited, Goa 403 722 INDIA For BluePoint Laboratories.
CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1584-2019 |
| Date reported | August 14, 2019 |
| Date initiated | February 19, 2019 |
| Recalling firm | American Health Packaging |
| Firm location | Columbus, OH |
| Affected scope | 14,360 bottles |
| Distribution | Nationwide within the USA and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 14, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.